Europe Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Global Market
Related Markets
Europe glp-1 agonists weight loss drugs market highlights
- The Europe glp-1 agonists weight loss drugs market generated a revenue of USD 2,263.4 million in 2025.
- The market is expected to grow at a CAGR of 9.99% from 2026 to 2033.
- In terms of segment, semaglutide (wegovy) was the largest revenue generating drug in 2025.
- Tirzepatide (Zepbound) is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 2,263.4 million |
| Market revenue in 2033 | USD 5,832.2 million |
| Growth rate | 9.99% (CAGR from 2026 to 2033) |
| Largest segment | Semaglutide (wegovy) |
| Fastest growing segment | Tirzepatide (Zepbound) |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Wegovy), Tirzepatide (Zepbound), Liraglutide (Saxenda), Other Drugs |
| Key market players worldwide | Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S ADR, Viking Therapeutics Inc, Structure Therapeutics |
Other key industry trends
- In terms of revenue, Europe region accounted for 10.8% of the global glp-1 agonists weight loss drugs market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- North America is the fastest growing regional market and is projected to reach USD 52,827.5 million by 2033.
The European GLP-1 agonists weight loss drugs market is experiencing rapid growth, largely driven by the rising awareness of Semaglutide (Wegovy) and the increasing popularity of other effective GLP-1 therapies such as Liraglutide (Saxenda).
These drugs are becoming a preferred option for weight management, particularly in countries like the UK, Germany, and France, where demand is rising steadily.
The market growth is being further fueled by the positive reception of GLP-1 agonists among healthcare providers and patients, as well as the increasing prevalence of obesity-related conditions.
No credit card required*
Publish Date: Feb 03, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
GLP-1 Agonists Weight Loss Drugs Market Scope
GLP-1 Agonists Weight Loss Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | www.vikingtherapeutics.com |
| Structure Therapeutics | View profile | 101-250 | South San Francisco, California, United States, North America | structuretx.com/ |
| Eli Lilly and Company | View profile | - | - | - |
Europe GLP-1 Agonists Weight Loss Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to GLP-1 Agonists Weight Loss Drugs Market Outlook will help companies and investors design strategic landscapes.
Semaglutide (Wegovy) was the largest segment with a revenue share of 79.63% in 2025.
Horizon Databook has segmented the Europe glp-1 agonists weight loss drugs market based on semaglutide (wegovy), tirzepatide (zepbound), liraglutide (saxenda), other drugs covering the revenue growth of each sub-segment from 2021 to 2033.
The European GLP-1 agonists weight loss drugs market is experiencing rapid growth, largely driven by the rising awareness of Semaglutide (Wegovy) and the increasing popularity of other effective GLP-1 therapies such as Liraglutide (Saxenda).
These drugs are becoming a preferred option for weight management, particularly in countries like the UK, Germany, and France, where demand is rising steadily.
The market growth is being further fueled by the positive reception of GLP-1 agonists among healthcare providers and patients, as well as the increasing prevalence of obesity-related conditions.
- Europe Glp-1 Agonists Weight Loss Drugs Market Drug Outlook (Revenue, USD Million , 2021-2033)
- Semaglutide (Wegovy)
- Liraglutide (Saxenda)
- Tirzepatide (Zepbound)
- Other Drugs
- Europe Glp-1 Agonists Weight Loss Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Parenteral
- Oral
- Europe Glp-1 Agonists Weight Loss Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Retail Pharmacies
- Hospital Pharmacies
- Other Pharmacies
Reasons to subscribe to GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of GLP-1 Agonists Weight Loss Drugs Market Outlook databook
- Our clientele includes a mix of GLP-1 Agonists Weight Loss Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe GLP-1 Agonists Weight Loss Drugs Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe GLP-1 Agonists Weight Loss Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Glp-1 Agonists Weight Loss Drugs Market, 2021-2033 (US$M)
Europe glp-1 agonists weight loss drugs market statistics, by drug, 2021-2033 (US$M)
